Drug intelligence / Profile preview

ISB 2301

Development stage: Preclinical
Lead developer: IGI Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ISB 2301 is a first-in-class natural killer (NK) cell engager currently in the discovery stage of development for the treatment of solid tumors. It is the lead program originating from the IMMUNITE™ platform, a proprietary technology of Ichnos Glenmark Innovation (IGI), which is an alliance between Ichnos Sciences and Glenmark Pharmaceuticals. As a multimodal immunotherapy, ISB 2301 is engineered to harness the innate immune system's cytotoxic potential by redirecting and activating NK cells to specifically target and eliminate solid tumor cells.

Targets

NCR2 (Natural cytotoxicity triggering receptor 2)

Beyond the preview

Go deeper on ISB 2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISB 2301.

Explore the full profile